Cargando…
IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
In this issue of JEM, Reijers et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Rockefeller University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035434/ https://www.ncbi.nlm.nih.gov/pubmed/36920330 http://dx.doi.org/10.1084/jem.20230160 |
| _version_ | 1784911411794673664 |
|---|---|
| author | Fukuda, Keitaro |
| author_facet | Fukuda, Keitaro |
| author_sort | Fukuda, Keitaro |
| collection | PubMed |
| description | In this issue of JEM, Reijers et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma. |
| format | Online Article Text |
| id | pubmed-10035434 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Rockefeller University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100354342023-09-15 IFNγ score–based neoadjuvant immunotherapy for stage III melanoma Fukuda, Keitaro J Exp Med Insights In this issue of JEM, Reijers et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma. Rockefeller University Press 2023-03-15 /pmc/articles/PMC10035434/ /pubmed/36920330 http://dx.doi.org/10.1084/jem.20230160 Text en © 2023 Fukuda https://creativecommons.org/licenses/by-nc-sa/4.0/http://www.rupress.org/terms/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
| spellingShingle | Insights Fukuda, Keitaro IFNγ score–based neoadjuvant immunotherapy for stage III melanoma |
| title | IFNγ score–based neoadjuvant immunotherapy for stage III melanoma |
| title_full | IFNγ score–based neoadjuvant immunotherapy for stage III melanoma |
| title_fullStr | IFNγ score–based neoadjuvant immunotherapy for stage III melanoma |
| title_full_unstemmed | IFNγ score–based neoadjuvant immunotherapy for stage III melanoma |
| title_short | IFNγ score–based neoadjuvant immunotherapy for stage III melanoma |
| title_sort | ifnγ score–based neoadjuvant immunotherapy for stage iii melanoma |
| topic | Insights |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035434/ https://www.ncbi.nlm.nih.gov/pubmed/36920330 http://dx.doi.org/10.1084/jem.20230160 |
| work_keys_str_mv | AT fukudakeitaro ifngscorebasedneoadjuvantimmunotherapyforstageiiimelanoma |